{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:47:10Z","timestamp":1791319630500,"version":"4.3.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T00:00:00Z","timestamp":1377820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"Summary<\/jats:title>Despite the recent development of effective therapeutic agents against multiple myeloma (MM<\/jats:styled-content>), new therapeutic approaches, including immunotherapies, remain to be developed. Here we identified novel human leucocyte antigen (HLA<\/jats:styled-content>)\u2010A*0201 (HLA<\/jats:styled-content>\u2010A2)\u2010restricted cytotoxic T<\/jats:styled-content> lymphocyte (CTL<\/jats:styled-content>) epitopes from a B<\/jats:styled-content> cell specific molecule HLA<\/jats:styled-content>\u2010DO\u03b2 (DOB<\/jats:styled-content>) as a potential target for MM<\/jats:styled-content>. By DNA<\/jats:styled-content> microarray analysis, the HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content><\/jats:italic> expression in MM<\/jats:styled-content> cells was significantly higher than that in normal plasma cells. Twenty\u2010five peptides were predicted to bind to HLA<\/jats:styled-content>\u2010A2 from the amino acid sequence of HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>. When screened for the immunogenicity in HLA<\/jats:styled-content>\u2010A2\u2010transgenic mice immunized with HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content><\/jats:italic> cDNA<\/jats:styled-content>, 4 peptides were substantially immunogenic. By mass spectrometry analysis of peptides eluted from HLA<\/jats:styled-content>\u2010A2\u2010immunoprecipitates of MM<\/jats:styled-content> cell lines, only two epitopes, HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>232\u2013240<\/jats:sub> (FLLGLIFLL<\/jats:styled-content>) and HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>185\u2013193<\/jats:sub> (VMLEMTPEL<\/jats:styled-content>), were confirmed for their physical presence on cell surface. When healthy donor blood was repeatedly stimulated in vitro<\/jats:italic> with these two peptides and assessed by antigen\u2010specific \u03b3\u2010interferon secretion, HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>232\u2013240<\/jats:sub> was more immunogenic than HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>185\u2013193<\/jats:sub>. Additionally, the HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>232\u2013240<\/jats:sub>\u2010specific CTL<\/jats:styled-content>s, but not the HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>185\u2013193<\/jats:sub>\u2010specific CTL<\/jats:styled-content>s, displayed an major histocompatibility complex class I<\/jats:styled-content>\u2010restricted reactivity against MM<\/jats:styled-content> cell lines expressing both HLA<\/jats:styled-content>\u2010A2 and HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>. Taken together, based on the physical presence on tumour cell surface and high immunogenicity, HLA<\/jats:styled-content>\u2010DOB<\/jats:styled-content>232\u2013240<\/jats:sub> might be useful for developing a novel immunotherapy against MM<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12544","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T05:26:38Z","timestamp":1377840398000},"page":"343-351","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identification of human leucocyte antigen (HLA<\/scp>)\u2010A*0201\u2010restricted cytotoxic T<\/scp> lymphocyte epitopes derived from HLA<\/scp>\u2010DO<\/scp>\u03b2 as a novel target for multiple myeloma"],"prefix":"10.1111","volume":"163","author":[{"given":"Yoon Joong","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Department of Biomedical Science Jungwon University Chungcheongbuk\u2010do South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Reinhold","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Choi","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Brusic","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Biostatistics Centre Kurume University Graduate School of Medicine Kurume Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Minvielle","sequence":"additional","affiliation":[{"name":"INSERM UMR 892 CNRS UMR 6299 University of Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis L.","family":"Reinherz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sasada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"},{"name":"Department of Immunology and Immunotherapy Kurume University School of Medicine Kurume Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-0995-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08850.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09111.x"},{"key":"e_1_2_8_5_1","first-page":"6846","article-title":"The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1\u2010specific cytotoxic T\u2010lymphocytes","volume":"61","author":"Brossart P.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2006.05.005"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0408"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06832.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00302.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1438"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404787"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.1.73"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(10)70006-2"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070209-175325"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-9-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.1301"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02879.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.4853"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2002.590608.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.4049\/jimmunol.156.7.2473","article-title":"Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non\u2010self MHC molecules","volume":"156","author":"Newberg M.H.","year":"1996","journal-title":"Journal of Immunology"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.04.009"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1925"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302607"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.08.011"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2224"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac102387t"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.126722"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181facf48"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277137"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119822"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0480-x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062387"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01442.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08286.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2012_057"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12544","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:06:53Z","timestamp":1696363613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,30]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/bjh.12544"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12544","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,30]]},"assertion":[{"value":"2013-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}